Pasteurization is an alternative to high-level disinfection or sterilization that does not require the use of chemicals. The device to be disinfected is submerged for у30 minutes in water whose temperature remains у165ºF. This study was undertaken to evaluate the efficacy of a pasteurization system to inactivate a variety of bacteria.
Contaminated respiratory-care equipment is a wellrecognized source of nosocomial respiratory tract infections. 1 For this reason, it is recommended that respiratorycare equipment be sterilized or high-level disinfected between patients. 2, 3 Failure to clean and disinfect ventilatory circuits properly between patients has led to outbreaks of Pseudomonas aeruginosa 4 and Acinetobacter calcoaceticus 5 infection.
Pasteurization is an alternative to high-level disinfection or sterilization that does not require the use of chemicals. The device to be disinfected is submerged for у30 minutes in water whose temperature remains у165ºF. This study was undertaken to evaluate the efficacy of a pasteurization system to inactivate a variety of bacteria.
METHODS

Evaluation of Pasteurization Efficacy
Test organisms were clinical isolates obtained from the University of North Carolina (UNC) Hospitals' Microbiology Laborator y (Klebsiella pneumoniae, Staphylococcus aureus, and Candida albicans), the American Type Culture Collection (ATCC), Rockville, Maryland (Mycobacterium terrae ATCC 15755), or Difco Laboratories, Detroit, Michigan (Bacillus subtilis). Organisms, except M terrae and B subtilis, were grown on sheep blood agar and inoculated to trypticase soy broth and the turbidity adjusted to match the 0. 5 McFarland standard. Surgical blades were aseptically placed in a sterile Petri dish and inoculated with 10 µL of this suspension in a biological safety cabinet. Porcelain penicylinders were allowed to sit in the inoculating suspension (1:10 dilution of 0.5 McFarland) for 10 to 15 minutes, then allowed to dry for 45 to 60 minutes at 37ºC. To evaluate sporicidal activity, carriers were inoculated with 10 µL of the spore suspension, allowed to air dr y overnight, and then stored for 7 days at room temperature before use.
For vegetative bacteria, carriers were quantitated in duplicate before use by placing the carrier in a test tube containing 10 mL of phosphate-buffered dilution water and vortexed for 1 minute. Serial 1:10 dilutions were made for each sample, with the last two dilutions of each set being plated in duplicate into trypticase soy agar with the pour-plate method. These plates were incubated at 37ºC for 48 hours and assessed for growth. The spore carriers were quantitated by placing the carrier in a test tube containing 10 mL of sterile water and sterile glass beads. These tubes were sonically treated for 5 minutes, chilled in an ice-water bath for 2 minutes, vortex mixed for 2 minutes, and then chilled again in an ice-water bath for 2 minutes. After these steps were repeated two more times, the samples were heat shocked for 15 minutes at 100ºC and then chilled in an ice-water bath. Serial dilutions (1:10ϫ4) were made for each sample, with the last two dilutions of each set being plated in duplicate into trypticase soy broth with the pour-plate method. These plates were incubated at 37ºC for 48 hours and assessed for growth.
The pasteurizer used in these experiments was a Steri-Vers Washer Plus (model 540-2; ClearMedical,
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Bellevue, WA). This device was leased by UNC Hospitals.
The microbicidal activity of the pasteurization process was assessed by aseptically placing inoculated carriers into 40-cm-long lumen test units ([LTUs] Figure) . Two types of LTUs were used. First, a stainless steel LTU with a removable 5-cm centerpiece (1.2-cm diameter) of stainless steel sealed to the narrower steel tubing by hard rubber septums. Second, a plastic LTU with a removable 5-cm centerpiece (1.2-cm diameter) of nalgene plastic sealed to the narrow plastic tubing by hard rubber septums. The lumen of both LTUs was 3-mm.
Two types of carriers were used: number 10 BardParker stainless steel surgical blades (Becton-Dickinson Acute Care, Franklin Lakes, NJ) were used in conjunction with the stainless steel LTUs, and porcelain cylinders were used with the plastic LTUs. The LTUs were then placed within the pasteurizer as recommended in the operating manual. Three or four LTUs were placed within each of the three layer dividers (total 10 LTUs) that fit into a stainless steel basket, the soap provided by the manufacturer was added, and the pasteurization cycle initiated. The temperature was monitored at each cycle, and the average temperature was 170.40ºF (range, 166º-173ºF). The mean disinfection cycle time was 30.45 minutes, and the total mean processing time was 81.82 miutes.
After completion of the pasteurization cycle, the carriers inoculated with S aureus, C albicans, K pneumoniae, or B subtilis were aseptically removed and placed in tubes containing trypticase soy broth. The tubes were incubated at 37ºC for 7 days. M terrae was placed in 7H9 broth and incubated for 7 days at 37ºC with CO 2 . Positive culture results were confirmed as representing the test organism using API 20E and API 50CH as appropriate (bioMérieux Vitek, Inc, Hazelwood, MO).
Estimation of Cost Savings
Cost estimates were based on the cost of the pasteurization equipment, straight-line depreciated over 10 years. The cost of pasteurization per cycle was estimated at $2.94 (equipment costs) plus $0.84 for soap. It was assumed that incorporation of pasteurization would not result in a change in labor, water, or utility expenses. Costs of the alternative sterilization method, ethylene oxide (ETO), were determined to be $103.76 ($97, ETO; $1.20, soap; $5.56, alcohol) per sterilization cycle based on actual costs of providing this service at UNC Hospitals. The totals reflect three cycles of pasteurization per day to accommodate the equipment and a single cycle of ETO per day (90% of available space used for respiratory-care equipment).
RESULTS
Microbial Inactivation
Pasteurization eliminated all vegetative bacteria whether placed in plastic or metal LTUs (Table) . Pasteurization was completely effective in eliminating C albicans and the highly resistant bacterium, M terrae. B subtilis, a spore-forming bacteria, was not completely eradicated from any carrier during 50 replicate tests at two concentrations.
Cost Savings
Based on these figures, the yearly cost of pasteurization is estimated to be $4,139 compared with a yearly cost of ETO of $34,085. Thus, pasteurization at our hospital will result in a yearly savings of $29,946.
DISCUSSION
Nosocomial pneumonia represents an important hazard for hospitalized patients, especially persons requiring mechanical ventilation. The incidence of ventilatorassociated pneumonia has ranged from 11 to 54 per 100 patients, depending on the population, and the crude FIGURE. Top: 40-cm-long and 3-mm-diameter stainless steel lumen test unit with stainless steel surgical-blade carrier. Once inoculated, the blade is aseptically placed in the removable center portion by unsealing the hard rubber septums connecting the stainless steel tubing. Bottom: 40-cm-long and 3-mm-diameter plastic lumen test unit with porcelain cylinder carrier. Once inoculated, the carrier is aseptically placed in the removable center portion by unsealing the hard rubber septums connecting the plastic tubing. mortality is in the range of 20% to 40%. 1, 6 Contaminated respirator y-care equipment represents an important potential cause of nosocomial pneumonia. For this reason, the Centers for Disease Control and Prevention recommends high-level disinfection or sterilization for semicritical equipment or devices that come into direct or indirect contact with mucous membranes of the lower respiratory tract. 2 Pasteurization is not a sterilization process; its purpose is to destroy all pathogenic vegetative microorganisms, but it may not destroy bacterial spores. The term high-level disinfection, a process that eliminates all microorganisms except high numbers of bacterial spores, is most commonly applied to chemical germicides, but data suggest that pasteurization may achieve similar microbial inactivation. The time-temperature relation for hot-water pasteurization is generally 70ºC (158ºF) for 30 minutes. This temperature is well under the temperature that would cause deleterious effects on plastic materials such as respirator y-therapy equipment. Pasteurization of respiratory therapy 7 and anesthesia 8 equipment is a recognized alternative to chemical disinfection. After pasteurization, the equipment is wet and is dried in hot-air dr ying cabinets prior to storage.
Our test system is a very stringent test of disinfection efficacy. The test carriers are inoculated with high numbers of test organisms and placed into the center of long narrow-lumened test units. Our system relies on passive rather than active flow to achieve contact between the test organism and the disinfecting solution (in this case, hot water). Further, a positive culture will result from a failure to eliminate all test organisms. In addition to testing metal tubing, we also tested plastic tubing in the belief that it would represent a more stringent test for a process that relies on heat for inactivation, because plastic would transfer heat less efficiently to the interior of the tubing.
Our data demonstrated complete elimination of high numbers of vegetative bacteria (S aureus, K pneumoniae), fungi (C albicans), and mycobacteria (M terrae). S aureus and K pneumoniae were chosen as test organisms because they are among the top four pathogens associated with nosocomial pneumonia. 9 C albicans was chosen since Candida species are the most common fungal causes of nosocomial infection. M terrae is increasingly used as a surrogate for M tuberculosis to test the efficacy of disinfectants. 10 Spores were not eliminated by the pasteurization process; however, sporeforming bacteria have only rarely been described as a risk factor for infection caused by contaminated respirator y therapy equipment. 11 Pasteurization was also demonstrated to be effective by Jette and Lambert, who used two hot-water washer-disinfectors and showed inactivation of A calcoaceticus, P aeruginosa, and bacteriophage Felix 01. 8 Other investigators have also demonstrated the efficacy of pasteurization. 12 However, Gurevich and associates 7 reported a disinfection failure rate of 83% when using a machine-assisted pasteurization process. These investigators experimentally contaminated 40-in-long tubing with ϳ10 7 P aeruginosa or A calcoaceticus. The reason for the disparity between our results and that of Gurevich and colleagues is unclear, although we note that that their tubing was approximately 2.5 times the length of our LTUs. It is likely that air bubbles or other incomplete water flow led to a failure of contact between the hot water and their test organisms.
Pasteurization was able to eliminate high numbers of a variety of bacteria, including mycobacteria, placed into the center of narrow-lumened test units. It is likely that this process would be even more effective with wider-bore tubing, presuming there is hot-water exposure of all surfaces. Although pasteurization did not eliminate B subtilis, only a single outbreak of Bacillus cereus infections has been described due to the failure of pasteurized respiratory-care equipment. 11 If additional outbreaks are reported, we may need to reassess this equipment.
In summary, we believe pasteurization is a safe, effective, and cost-effective method for disinfecting respiratory-care equipment.
Within the past 2 decades, Candida species have emerged as major human pathogens and are currently the fourth most common cause of nosocomial bloodstream infection. 1 The incidence of nosocomial candidemia has risen fivefold in the past 10 years, with Candida albicans being the most frequently isolated organism. 2 This increase may reflect the increase in the number of immunocompromised patients and the more frequent use of invasive techniques that lead to extended hospitalization. 3 Recent studies have documented a slight increase in the proportion of bloodstream infections due to species other than C albicans, 1,4,5 Candida guilliermondii, described as the ascomycetous yeast of Yamadazyma guilliermondii, is found on human skin and as part of the genitourinary and gastrointestinal tract flora. 6 It is well documented to cause endocarditis in intravenous drug addicts, infection in patients undergoing surgical procedures, and fungemia in immunocompromised patients. 3, 6 Because it is considered part of the emerging opportunistic fungi being recovered more frequently in severely immunocompromised cancer patients, we conducted this retrospective study of C guilliermondii fungemia in cancer patients over a 10-year period, with a special focus on nosocomial cases.
METHODS
All cases of C guilliermondii fungemia diagnosed at the University of Texas M.D. Anderson Cancer Center between January 1988 and December 1998 were identified through the records of the Department of Microbiology. The hospital course of the patients was retrospectively reviewed for information on the following characteristics: age, gender, underlying disease, duration of hospitalization before first positive blood culture, duration of neutropenia, antifungal prophylaxis, parenteral hyperalimentation, and immunosuppressive therapy (with antineoplastic agents and steroids) administered within 30 days prior to infection. Data also were collected on factors present at onset of infection, including the underlying disease and its treatment, the neutrophil count, concomitant non-candidal infection (within 1 week of onset of Candida infection), and the presence of a central venous catheter (CVC).
The physiological and other parameters needed to compute the Acute Physiological and Chronic Health Evaluation (Apache) II score were noted.
Candidemia was defined as the isolation of C guilliermondii from at least one blood-culture specimen from a patient with signs and symptoms of infection. Neutropenia was defined as a neutrophil count <1,000/mm 3 .
RESULTS
We identified nine cases of C guilliermondii fungemia from Januar y 1988 to December 1998 in immunocompromised cancer patients at our institution. Five of the nine patients acquired the infection during their hospital stay 10 to 45 days after admission and were considered as nosocomial, while the remaining four were considered community-acquired infections, as they appeared within 4 days following admission. Two thirds of the patients had leukemia in relapse, and one third had solid tumor as the primary disease. The median age of all patients was 40 (range, 20-82) years. The mean Apache II score was 14 (range, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . The median duration of hospitalization before the first C guilliermondii-positive blood culture was 10 (range, 0-45) days. The median duration of neutropenia was 15 (range, 3-52) days. The number of positive blood cultures for C guilliermondii was between one and four for each patient. Concomitant infections were observed in five of the nine patients.
Fungemia was associated with fever in all nine patients, pneumonia in three patients, mucositis in three patients, and skin lesion in two patients. Almost all of the patients (8/9) received intensive chemotherapy and broad-spectrum antibiotics prior to the fungemia. Three patients received steroids. Two thirds of the patients had prolonged neutropenia (>14 days) with median duration of 15 (range, 3-52) days. At the time of fungemia, eight patients had a CVC, with only one nosocomial, probably catheter-related, fungemia (7 colony-forming units/mL of C guilliermondii grew from blood drawn through the CVC, with no evident source for the fungemia except the CVC). Most of the fungemias (5/9) occurred as a breakthrough infection on antifungal drugs with agents such as fluconazole (200-400 mg/kg/d), liposomal amphotericin B (5 mg/kg/d), and itraconazole (400 mg/d). Six patients received antifungal treatment with azoles or amphotericin compounds, with variable outcomes. Four of the five hospital-acquired C guilliermondii fungemias were associated with multiple positive blood cultures, profound neutropenia, and intensive chemotherapy; all had a fatal outcome (Table) . However, all four of the patients with community-acquired fungemia survived, irrespective of their underlying disease, risk factors, and treatment, even though one half of them did not receive any treatment.
